SCHEMBL2407705

SCHEMBL2407705

COc1ccc(/C=C/c2nc(CC3CCN(C(=O)OC(C)(C)C)CC3)no2)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.43
PDE4A P27815 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
BCHE P06276 4/20 0.41
MAOA P21397 4/20 0.41
ACHE P22303 4/20 0.41
MAOB P27338 4/20 0.41
ALOX5 P09917 2/20 0.40
EPHA2 P29317 1/20 0.40
KDR P35968 1/20 0.40
EPHB4 P54760 1/20 0.40
STS P08842 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407707 1.00 PDE4B (0.43) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL16480368 0.88 TP53 (0.41) MAPTMEN1KMT2A
SCHEMBL13633439 0.85 GPR119 (0.49) USP30
SCHEMBL389696 0.82 GPR119 (0.48)
SCHEMBL389697 0.82 GPR119 (0.48)
SCHEMBL2411348 0.81 ALOX5 (0.42) PDE4BMAPTSMN1; SMN2BCHEMAOA
SCHEMBL2407227 0.80 MAPT (0.48) MAPTSMN1; SMN2ALOX5
SCHEMBL2407229 0.80 MAPT (0.48) MAPTSMN1; SMN2ALOX5
SCHEMBL2407869 0.80 KDM4E (0.41) MAPTSMN1; SMN2BCHEMAOAACHE
SCHEMBL2407867 0.80 KDM4E (0.41) MAPTSMN1; SMN2BCHEMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629277-B2 Styrenyl 1,2,4-oxadiazole compounds Piramal Enterprises Limited (IN) 2014-01-14 US claimed
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-03 US claimed
EP-2539327-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-02 EP claimed
WO-2011104680-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-09-01 WO claimed
US-8629277-B2 Styrenyl 1,2,4-oxadiazole compounds Piramal Enterprises Limited (IN) 2014-01-14 US disclosed
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-03 US disclosed
EP-2539327-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-02 EP disclosed
WO-2011104680-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE MCL1, OXA1L, ABL1 PDE4B 824/4885PDE4A 1203/4885PDE4C 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.